Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




RDW Blood Test Can Predict Mortality and Re-Admission Among Elderly, Hospitalized Patients

By LabMedica International staff writers
Posted on 25 May 2022

Red cell distribution width (RDW), an index for variation of red blood cell size, has been proposed as a potential marker for poorer outcomes in several aging-related diseases and conditions. More...

The biological mechanisms linking greater variability of RBC size and adverse health-related outcomes are not known, however emerging evidence supports the use of RDW as a marker for biologic aging, disease vulnerability, oxidative stress and chronic inflammation. Now, new research has found that higher RDW is associated with increased rates of in-hospital mortality and hospital re-admission among older (>60) patients.

In a retrospective analysis, investigators at Sutter’s California Pacific Medical Center (CPMC, Davis, CA, USA) studied 94,617 patients aged >60 who were hospitalized between January 2013 to December 2017 at Sutter Health. A total of 167,292 admissions were included. The RDW was measured during hospital admission and categorized with 1% intervals. The primary outcome was the rate of in-hospital mortality; secondary outcomes included 30-day re-admission rate and length of hospital stay.

Results showed the overall in-hospital mortality rate was 6.3%. As the RDW value increased, the rate of in-hospital mortality increased from 2.7% for the lowest RDW category to 12.2% in the highest category (p-trend <0.001). The overall 30-day re-admission rate after discharge was 12.5% and the rate of 30-day readmission also increased with increasing RDW categories (7.4% in the lowest group vs. 15.8% in the highest group, p-trend <0.001). Patients with the highest RDW values at admission stayed 1.5–2.0 times longer in the hospital than patients with lower RDW values who were admitted for the same causes.

“Greater variability of red blood cell size is significantly associated with worse prognosis in hospitalized elderly patients, indicating higher mortality, greater risk of early re-admission and longer hospital stay days. Risk stratification strategies for hospitalized elderly should include RDW value,” said Steve Cummings, M.D., lead author of the study, director of the SFCC and a principal investigator at CPMC.

“Predicting the risk of mortality and re-admission are critical for in-patient care. An accurate risk classification strategy for patients can also improve outcomes in clinical practice,” added Warren Browner, M.D., co-author of the study and CEO of CPMC. “However, there are no strong predictors of mortality or early re-admission that can be applied across multiple aging-related diseases. These findings provide the potential of RDW value, one of the most common laboratory tests that are performed for most hospitalized patients, as a biomarker for poorer prognosis or vulnerability in hospitalized elderly patients.”

Related Links:
CPMC 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The approach uses in-house pathology tests and streamlined access to specialists to shorten the diagnostic pathway for children with immune conditions. (Image Credit: iStock)

Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis

Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More than 500 of these rare disorders... Read more

Immunology

view channel
Image: Acute myeloid leukemia is the first of several disease areas the collaborators plan to pursue together as part of efforts to advance precision diagnostics (Image Credit: Adobe Stock)

Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.